Xilio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xilio Therapeutics (XLO).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$33Upside to Avg. PT+339.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Raymond James	Sean McCutcheon	Initiate	Outperform	$16
Aug 6, 2025	Leerink Partners	Daina Graybosch	Initiate	Outperform	$28
Nov 8, 2024	Raymond James	Dane Leone	PT Cut	Outperform	$84→$56

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

Raymond James analyst Dane Leone maintains Xilio Therapeutics (NASDAQ:XLO) with a Outperform and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $20 to $10.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

Benzinga Insights

Xilio Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Xilio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

People Also Watch

People Also Watch

Xilio Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Xilio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORaymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRORaymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PROChardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PROChardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PROMorgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10